The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of rapid multigene assays with short turnaround time (TAT) on the development of precision medicine for non-small cell lung cancer (NSCLC).
 
Shingo Matsumoto
Honoraria - AstraZeneca; Chugai Pharma; Guardant Health; Novartis; Pfizer; Thermo Fisher Scientific
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst)
 
Takaya Ikeda
No Relationships to Disclose
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Kirin Pharmaceuticals; Lilly Japan; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Akira Sugimoto
Stock and Other Ownership Interests - Japan Tobacco Inc; Takeda
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Merck Sharp & Dohme; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Lilly; Merck Serono; MSD; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono; Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst)
 
Kei Kunimasa
No Relationships to Disclose
 
Atsushi Nakamura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD
 
Ichiro Nakachi
No Relationships to Disclose
 
Shoichi Kuyama
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kyorin; Meiji Seika Kaisha; MSD; Pfizer; Taiho Pharmaceutical
 
Jun Sakakibara-Konishi
No Relationships to Disclose
 
Haruko Daga
Honoraria - Chugai/Roche; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai/Roche (Inst); Lilly (Inst)
 
Eiji Iwama
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Novartis; Pfizer
Consulting or Advisory Role - Chugai Pharma
 
Kageaki Taima
No Relationships to Disclose
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim
 
Kaname Nosaki
Honoraria - AstraZeneca; Chugai Pharma; Janssen; Lilly; MSD; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca; Takeda (Inst)
 
Hiroki Izumi
No Relationships to Disclose
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); MSD (Inst)
 
Koichi Goto
Honoraria - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; MSD K.K.; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Amgen; Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; Eisai; Ignyta; Janssen; Kissei Pharmaceutical; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck; Merus; MSD K.K.; NEC Corporation; Ono Pharmaceutical; Pfizer; Shanghai HaiHe Pharmaceutical; Spectrum Pharmaceuticals; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Takeda; Xcoo